Hunan Huateng Pharmaceutical Co., Ltd. is a research-based manufacturer and supplier of combinatorial building blocks, organics and fine chemicals, with 5000m2 laboratory and over 100 experienced chemists. Huateng is dedicated to bring high quality and cost effective chemical products and services to our clients. Our versatile chemical synthesis ex...
Hunan Huateng Pharmaceutical Co., Ltd. is a research-based manufacturer and supplier of combinatorial building blocks, organics and fine chemicals, with 5000m2 laboratory and over 100 experienced chemists. Huateng is dedicated to bring high quality and cost effective chemical products and services to our clients. Our versatile chemical synthesis expertise and manufacturing capability prepare us to produce a variety of known, novel or even hard-to-find chemicals from kg to ton scale.
Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989. We initially started producing Trimethoprim IP/BP with in-house developed technology. During the first year of its operation, the Company had expanded the producti...
Shilpa Medicare Limited (SML) started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989. We initially started producing Trimethoprim IP/BP with in-house developed technology. During the first year of its operation, the Company had expanded the production facilities to manufacture Trimethoprim apart from selling on its own, for other reputed Companies like Eskayef Limited, Bombay Drugs and Pharmas Limited, Bombay Drug House Ltd., US Vitamins Ltd, Sandoz India Ltd etc. for their export commitments.
Near 1992, the Company had further enhanced its operations by inducting new production facilities for manufacture of Sodium Methoxide. The technology for the Sodium Methoxide was also developed in house. About the same time, the Company secured export business from Stellar Exports Limited, Glaxo Limited and Deepak Nitrite Limited for Trimethoprim. Since then Shilpa Medicare Limited has started exporting on its own. The Company thus started manufacturing for both export and domestic markets since 1992.
The Company then embarked upon an expansion project which involved the addition of one more bulk drugs to its existing product range viz; Norfloxcin and expansion of the production capacity of the existing products of the Company viz; Sodium Methoxide and Trimethoprim. The Company also developed a process for drug intermediate- 1-methyl amino-1-methylthio- 2-nitro ethane, used in the manufacture of Ranitidine, which is an anti-ulcer drug. In November 1993, Shilpa Medicare was converted into a Public Limited Company. The Company was listed on Bombay Stock Exchange on Jun 19, 1995 and National Stock Exchange (NSE) on Dec 03, 2009.Subsequently; Shilpa Medicare has gained World Health Organization-Good Manufacturing Practices (GMP) Certificate recognition. In our relentless efforts for growth-Shilpa Medicare successfully set up a 100% EOU project in FY10 incurring a capital expenditure of nearly Rs.1000 million.
Today, we have carved a niche for ourselves in the exceedingly competitive and quality-conscious field of pharmaceuticals manufacturing. We aim to be amongst global leaders in generic APIs & pharmaceutical products manufacturers, finding innovative ways to make affordable medicines accessible to every section of the society. SML is committed to its mission of achieving affordable healthcare, which shall be available to more and more people globally. ‘Global access to affordable healthcare’- is how we see ourselves contributing to the field of medicine.
We are dealing with high-quality Active Pharmaceutical Ingredients (APIs), Intermediates, Formulations, New Drug Delivery Systems, Peptides / Biotech products and Specialty Chemicals etc. utilizing sophisticated technology meticulously in order to comply with international standards/specifications. Today we are among the world’s leading suppliers of Oncology/non- Oncology APIs and intermediates. Further to consolidation in field of generic APIs and Formulations, we are striving for achieving excellence by putting our relentless efforts in field of Novel Drug Delivery Systems (NDDS) and peptides/biotechnology, along with widening our focus to other therapy areas. We aim for ensuring affordable healthcare without compromising quality standards.
We are ISO 14001: 2004 certified organization and committed to implement, maintain and improve the environmental management system so as to assure its conformity with our stated environmental policy. We offer a broad and integrated portfolio of products and services (CRAMS) to the global pharmaceutical industry. In recognition of our outstanding performance we have been awarded time to time, with awards like ‘Best Entrepreneur Award’ and ‘Star Export House’ by Ministry of Commerce and Industry, Govt. of India and National Energy Conservation Award-2012 by President of India.
Being proactive in approach, we continuously seek out avenues and first available opportunities for development of new products drawing strength from our zeal to provide affordable healthcare to everyone. Our state-of-the-art infrastructure, more than 2 decades of experience, and rigorous across-the-board quality standards all contribute to our commitment- Quality Healthcare at a price which everyone can afford. Being Shilpa Medicare companies, our vision and business plans are shared by our subsidiary organizations:
Raichem Life Sciences
At Shilpa in our state of art facilities, we bring on board the expertise and passion for excellence of our competent team to develop quality pharmaceuticals while building value to our partners and stakeholders. We are known as a successful and reliable partner within the pharmaceutical domain. Buyers within the country and from across the borders count on our fast track integrated development plans. Shilpa Medicare’s skilled team and certified manufacturing capabilities have proved to be significant differentiator among discerning buyers in the highly regulated markets of US and Europe. Besides exporting to USA, Canada, Australia, Japan and European Countries viz.,Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., we also cater to South American Countries like Mexico, Brazil, and Columbia etc.; African Countries like Kenya, Nigeria and West Indies etc. and Asian Countries like Singapore, Taiwan, China, Malaysia, Thailand, etc.
Shilpa Medicare’s facilities have received key regulatory approvals for its facilities as well as for the products from EDQM, UK-MHRA, TGA, USFDA, PMDA and KFDA. With diverse regulatory recognized manufacturing set ups and excellent scientific manpower, Shilpa has been on a consistent growth path, thus defining us: Shilpa Medicare-“Where growth is a habit”.
At Shilpa Medicare, we make every effort to create an environment of openness and transparency. We believe in maintaining the trust and respect of all of our stakeholders and customers by acting with integrity at all times. Our ultimate goal is to help all levels of society in living healthier lives